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Introduction and Aims: Atypical haemolytic uraemic syndrome (aHUS) is a rare,
genetic life-threatening disorder characterised by thrombotic microangiopathy
(TMA) and end organ damage. Clinical manifestations of TMA are seen
throughout disease progress and, historically, outcomes have been poor. Prospective
clinical trials (100 patients [pts]) have shown eculizumab (Ecu), a monoclonal
antibody blocking terminal complement, to inhibit complement-mediated TMA
and be well tolerated in pts with aHUS. Life-long treatment with Ecu is indicated
for pts with aHUS due to risk of TMA, but discontinuation of treatment has been
attempted.
Methods: A retrospective analysis of a series of selected cases of 6 pts with
aHUS where Ecu therapy was discontinued or altered from the indicated dosing
regimen.
Results: Pt details including genetic mutation, duration of Ecu treatment and
outcomes post Ecu discontinuation are described in the table. During Ecu
treatment, all pts demonstrated improvement or normalisation of haematological
parameters and no new TMA manifestations. Four pts had improved renal function,
while 2 remained on dialysis. The median time on indicated Ecu dose was 5.2 (range
1–14) months and the median time to new TMA post-discontinuation was 3 (range
2–12) months. Two pts have not had any new TMA manifestations following
alteration or discontinuation of the approved dosing regimen. Pt 4 has continued to
receive Ecu at a reduced dose (900 mg/month) for 12 months and pt 6 discontinued
Ecu and has been followed-up for 19 months.
Conclusions: Discontinuation of chronic Ecu treatment in this case series of pts
with aHUS led to new TMA manifestations in 4/6 pts (2 without identified
mutations, 1 with an MCP mutation and 1 with a C3 mutation) requiring
re-initiation of Ecu. These findings highlight the importance of sustained
complement blockade in pts with aHUS.
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